Treatment of Exercise-Induced Pulmonary Vascular Dysfunction in Symptomatic Patients After Pulmonary Thromboendarterectomy
| Status: | Not yet recruiting |
|---|---|
| Conditions: | Cardiology |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - 100 |
| Updated: | 1/6/2019 |
| Start Date: | April 2019 |
| End Date: | May 2020 |
| Contact: | Cheri Abbott, RN |
| Email: | Cheryl.Abbott@ucdenver.edu |
| Phone: | 303-724-7466 |
This is an open label study of Riociguat in patients with continued exercise intolerance at
least 6 months following pulmonary endarterectomy (PEA).
least 6 months following pulmonary endarterectomy (PEA).
Inclusion Criteria:
- Adult patients who underwent PTE for Chronic thromboembolic pulmonary hypertension
(CTEPH) at least six months prior to screening and report ongoing subjective exercise
limitation,
- able to give consent
- able to perform a exercise protocol
Exclusion Criteria:
- Patients with known Residual Pulmonary Hypertension (RPH) by RHC following PTE for
CTEPH
- ongoing PAH-specific vasodilator therapy
- known contraindication to riociguat
- a physical limitation to completing an exercise protocol
We found this trial at
1
site
13001 E 17th Pl
Aurora, Colorado 80045
Aurora, Colorado 80045
(303) 724-5000
Principal Investigator: Todd Bull, MD
Phone: 303-724-7466
University of Colorado Anschutz Medical Campus Located in the Denver metro area near the Rocky...
Click here to add this to my saved trials
